Certara, Inc.

CERT

$7.95

-2.28%

N/A-$0.19

Salud

Medicina - Servicios de Información de Atención Médica

NASDAQ

Negociación activa

Certara, Inc. provee soluciones de software avanzadas y servicios impulsados por tecnología, especializándose en biosimulación a lo largo de todo el ciclo ...

Métricas clave de CERT

Instantánea

Último / TTM · 6 periodos

Capitalización

$1.24B

ROCE

0.6%

EV / EBITDA

16.13x

-0.9% YoY

Rendimiento FCF

5.0%

+0.0% YoY

Ciclo de conversión de efectivo

95.9d

Ratio corriente

2.55

Resumen rápido

TTM —

Positive CCC

Métricas clave

Último / TTM · 6 periodos

Tendencia de valoración

Tendencia de valoración table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$4.26B	$2.52B	$2.80B	$1.71B	$1.41B	$1.24B
Enterprise ValueCompany value including debt and cash adjustments.	$4.38B	$2.59B	$2.86B	$1.84B	$1.24B	$1.34B
EV / SalesHow many dollars investors pay per dollar of sales.	15.31x	7.72x	8.08x	4.78x	2.95x	3.29x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	74.79x	29.13x	120.08x	25.44x	14.72x	16.13x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	2.09	0.80	2.84	1.83	-2.12	1.29

Retornos + indicador ROCE

ROCE más reciente

0.6%

Prev year 1.5%

Retornos + indicador ROCE table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-1.3%	1.4%	-5.3%	-1.1%	-0.2%	-6.7%
ROAProfit generated from total assets.	-0.9%	0.9%	-3.5%	-0.8%	-0.1%	-4.9%
ROICReturn generated on invested operating capital.	3.7%	2.0%	-2.3%	0.2%	-0.4%	2.8%
ROCEOperating return on long-term capital used.	1.0%	2.2%	-2.8%	-0.1%	1.5%	0.6%
Earnings YieldEarnings as a percentage of market value.	-0.3%	0.6%	-2.0%	-0.7%	-0.1%	-5.6%

Calidad del flujo de caja

Calidad del flujo de caja table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$117.67M	$93.97M	$90.44M	$74.52M	$65.64M	$104.79M
FCFECash flow available to equity holders after debt flows.	$47.60M	$76.70M	$64.39M	$63.48M	$66.78M	$58.67M
FCF YieldFree cash flow divided by market capitalization.	1.2%	3.2%	2.4%	3.5%	4.9%	5.0%
Income QualityHow well accounting earnings are backed by cash flow.	-4.55	6.28	-1.49	-6.68	-60.39	-3.72
Capex / OCFShare of operating cash flow spent on capital expenditures.	14.7%	13.5%	18.5%	26.1%	27.6%	25.6%

Eficiencia operativa

Eficiencia operativa table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	99.9d	96.6d	96.1d	112.9d	101.3d	101.8d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	24.4d	20.7d	13.4d	8.3d	7.8d	5.8d
Operating CycleTime from buying inventory to collecting receivables.	99.9d	96.6d	96.1d	112.9d	101.3d	101.8d
Cash Conversion CycleNet days cash is tied in operations.	75.5d	75.8d	82.7d	104.6d	93.6d	95.9d

Instantánea

Último / TTM: —

Capitalización

$1.24B

ROE

-6.7%

Rendimiento FCF

5.0%

Ratio corriente

2.55

Cadena de suministro de CERT

Upstream / Downstream / Proxy

Upstream

Amazon Web Services (AWS)NASDAQ:AMZN Microsoft AzureNASDAQ:MSFT Google Cloud Platform (Alphabet)NASDAQ:GOOGLTetraScienceXybion DigitalNVIDIA CorporationNASDAQ:NVDA

Downstream

Pfizer Inc.NYSE:PFE Novartis AGNYSE:NVS Roche Holding AGOTC:RHHBY Merck & Co., Inc.NYSE:MRK Johnson & JohnsonNYSE:JNJ AstraZeneca PLCNASDAQ:AZN AbbVie Inc.NYSE:ABBV GSK plcNYSE:GSK Bristol-Myers Squibb CompanyNYSE:BMY Sanofi S.A.NASDAQ:SNYU.S. Food and Drug Administration (FDA)European Medicines Agency (EMA)Pharmaceuticals and Medical Devices Agency (PMDA) - JapanNational Medical Products Administration (NMPA) - ChinaAltasciencesTri-I BiotechT&J TechAKT Health / AKT Health AnalyticsNaizak GlobalEpista Life SciencesA2Healthcare CorporationBiTek ChemsGNX TechBiowaived

Empresas proxy

Simulations Plus, Inc.NASDAQ:SLP Schrödinger, Inc.NASDAQ:SDGR Dassault Systèmes SE (BIOVIA brand)OTCMKTS:DASTY

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal